Table 1.
List of Select Multi-step and Single-Step Selected Cell Lines Overexpressing ABC Transporters
| Selection Regimen | Cell Line | Drug | ABC Transporter Overexpressed |
|---|---|---|---|
| Multi-step | KB-3-1 | Colchicine | ABCB1 (13) |
| Doxorubicin | ABCB1 (13) | ||
| Vinblastine | ABCB1 (13) | ||
| Multi-step | OVCAR-8 | Doxorubicin | ABCB1 (14; 15) |
| Multi-step | MCF-7 | Doxorubicin | ABCB1 (17) |
| Multi-step | MES-SA | Doxorubicin | ABCB1 (19) |
| Multi-step | MCF-7 | Docetaxel | ABCB1 (20) |
| Multi-step | MDA-MB-231 | Docetaxel | ABCB1 (20) |
| Multi-step | MCF-7 | Doxorubicin | ABCB1 and ABCG2 (21; 22) |
| Multi-step | MCF-7 | Paclitaxel | ABCB1 and ABCG2 (21; 22) |
| Multi-step | NCI-H69 | Doxorubicin | ABCC1 (23) |
| Multi-step | COR-L23 | Doxorubicin | ABCC1 (24; 25) |
| Multi-step | MOR | Doxorubicin | ABCC1 (24; 25) |
| Multi-step | GLC4 | Doxorubicin | ABCC1 (26) |
| Multi-step | MCF-7 | Etoposide | ABCC1 (27) |
| Multi-step | NCI-H69 | Etoposide | ABCB1 and ABCC1 (28) |
| Multi-step | MCF-7 | Flavopiridol | ABCG2 (29) |
| Multi-step | MCF-7 | Doxorubicin and verapamil |
ABCG2 (30) |
| Multi-step | MCF-7 | Mitoxantrone | ABCG2 (31) |
| Multi-step | S1 | Mitoxantrone | ABCG2 (32) |
| Multi-step | IGROV-1 | Topotecan | ABCG2 (33) |
| Multi-step | IGROV-1 | Mitoxantrone | ABCG2 (33) |
| Multi-step | SF295 | Mitoxantrone | ABCG2 (34) |
| Multi-step | GLC4 | Mitoxantrone | ABCA2 (35) |
| Single-step | MCF-7 | Doxorubicin | ABCC4 and ABCG2* (10) |
| Single-step | MCF-7 | Etoposide | ABCG2 (10) |
| Single-step | IGROV-1 | Doxorubicin | ABCG2 (10) |
| Single-step | S1 | Doxorubicin | ABCG2 (10) |
| Single-step | MES-SA | Doxorubicin | ABCB1 (57) |
| Single-step | MES-SA | Paclitaxel | ABCB1 (59) |
| Single-step | NCI-H82 | Epirubicin | ABCC1 (62) |
| Single-step | GLC4 | Doxorubicin | ABCC1 (63) |
In all cases the overexpression of an ABC transporter was demonstrated at the functional level and the references are given in the parenthesis.
*
ABCG2 is the ABC transporter responsible for MDR and ABCC4 does not confer resistance to doxorubicin.